Latest Breaking News On - Impel neuropharma inc - Page 7 : comparemela.com

Impel NeuroPharma to Host Virtual Key Opinion Leader Event on August 6, 2021 July 29, 2021 08:00 ET | Source: Impel NeuroPharma Impel NeuroPharma Seattle, Washington, UNITED STATES SEATTLE, July 29, 2021 (GLOBE NEWSWIRE) Impel NeuroPharma, Inc. (NASDAQ: IMPL), a late-stage biopharmaceutical company focused on the development and commercialization of transformative therapies for patients living with central nervous system (CNS) diseases with high unmet medical needs, today announced that it will host a virtual key opinion leader (KOL) event to review the post triptan failure landscape and new options for the treatment of acute migraine. In addition, the program will cover the role of non-oral acute migraine therapies, including the history of use of dihydroergotamine (DHE), the STOP301 trial results for Impel’s lead product candidate TRUDHESA™ and commercial insights and opportunities in the acute migraine market. The event

United statesWade cooperChristina tartagliaMelyssa weibleStewart tepperNada hindiyehStanford medical schoolGeisel school of medicineImpel neuropharma incElixir health public relationsUniversity of michigan school medicineDartmouth headache centerNeuropathic painMichigan schoolGeisel schoolAssistant professor